scispace - formally typeset
Open AccessJournal ArticleDOI

Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment.

TLDR
The findings substantiate the importance of ventricular remodeling as central in the pathophysiology of advancing heart failure and support the role of measures of LV remodeling in the clinical investigation of novel heart failure treatments.
Abstract
Ventricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs progressively in untreated patients after large myocardial infarction and in those with dilated forms of cardiomyopathy. The gross pathologic changes of increased LV volume and perturbation in the normal elliptical LV chamber configuration is driven, on a histologic level, by myocyte hypertrophy and apoptosis and by increased interstitial collagen. Each of the techniques used for tracking this process—echocardiography, radionuclide ventriculography, and cardiac magnetic resonance—carries advantages and disadvantages. Numerous investigations have demonstrated the value of LV volume measurement at a single time-point and over time in predicting clinical outcomes in patients with heart failure and in those after myocardial infarction. The structural pattern of LV remodeling and evidence of scarring on cardiac magnetic resonance have additional prognostic value. Beyond the impact of abnormal cardiac structure on cardiovascular events, the relationship between LV remodeling and clinical outcomes is likely linked through common local and systemic factors driving vascular as well as myocardial pathology. As demonstrated by a recent meta-analysis of heart failure trials, LV volume stands out among surrogate markers as strongly correlating with the impact of a particular drug or device therapy on patient survival. These findings substantiate the importance of ventricular remodeling as central in the pathophysiology of advancing heart failure and support the role of measures of LV remodeling in the clinical investigation of novel heart failure treatments.

read more

Citations
More filters
Journal ArticleDOI

A review of cardiovascular benefits of SGLT2 inhibitors.

Yingxia Zhang, +1 more
- 09 Sep 2022 - 
TL;DR: This review discusses the current concepts and possible mechanisms of SGLT2I in the treatment of heart failure, myocardial infarction, hypertension, cardiomyopathy and arrhythmia to provide a reference for clinicians to use drugs more reasonably and scientifically.
Journal ArticleDOI

New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling.

TL;DR: In this paper , a review briefly investigates the molecular mechanisms of SGLT2 inhibitors on ameliorating ventricular remodeling, and further explore the mechanisms of cardiovascular protection of sGLT 2 inhibitors, in order to establish strategies for ventricular removeling to prevent the progress of heart failure.
Journal ArticleDOI

A review of cardiovascular benefits of SGLT2 inhibitors

TL;DR: Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney as discussed by the authors , which has been found to have multiple protective effects, such as hypoglycemia, cardio-renal protective, antihypertensive, and lipid-lowering effects.
Book ChapterDOI

Current Status of Heart Transplantation

TL;DR: Alternative strategies for heart replacement therapy including the emergence of ventricular assist devices are assuming a larger supportive role for those awaiting a donor heart, reflecting the need for robust multicenter randomized immunosuppression trials.
References
More filters
Journal ArticleDOI

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI

Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction

TL;DR: The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure.
Journal ArticleDOI

The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.

TL;DR: Reversible myocardial dysfunction can be identified by contrast-enhanced MRI before coronary revascularization and is strongly related to the degree of improvement in the global mean wall-motion score and the ejection fraction after Revascularization.
Related Papers (5)